


Linagliptin-¹³C,₃D₃

| | |
|---------------------------|---|
| Cat. No.: | HY-10284S1 |
| CAS No.: | 1398044-43-3 |
| Molecular Formula: | C ₂₄ ¹³ CH ₂₅ D ₃ N ₈ O ₂ |
| Molecular Weight: | 476.55 |
| Target: | Dipeptidyl Peptidase; Autophagy; Ferroptosis; Isotope-Labeled Compounds |
| Pathway: | Metabolic Enzyme/Protease; Autophagy; Apoptosis; Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | Linagliptin- ¹³ C, ₃ D ₃ is the ¹³ C- and deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC ₅₀ of 1 nM. Linagliptin- ¹³ C, ₃ D ₃ is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups. |
| IC₅₀ & Target | DPP-4 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[82] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Eckhardt M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d
- [2]. Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. *Sci Rep.* 2017 Jun 28;7(1):4351.
- [3]. Schurmann C, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. *J Pharmacol Exp Ther.* 2012 Jul;342(1):71-80.
- [4]. Thomas L, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action
- [5]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-223.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA